- Home
- NGS vs ANNX Comparison
NGS vs ANNX Comparison
Compare NGS & ANNX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- NGS
- ANNX
- Stock Information
- Founded
- NGS 1998
- ANNX 2011
- Country
- NGS United States
- ANNX United States
- Employees
- NGS N/A
- ANNX N/A
- Industry
- NGS Oilfield Services/Equipment
- ANNX Biotechnology: Pharmaceutical Preparations
- Sector
- NGS Energy
- ANNX Health Care
- Exchange
- NGS Nasdaq
- ANNX Nasdaq
- Market Cap
- NGS 304.4M
- ANNX 263.3M
- IPO Year
- NGS 2002
- ANNX 2020
- Fundamental
- Price
- NGS $24.32
- ANNX $2.48
- Analyst Decision
- NGS Strong Buy
- ANNX Strong Buy
- Analyst Count
- NGS 2
- ANNX 4
- Target Price
- NGS $32.50
- ANNX $12.50
- AVG Volume (30 Days)
- NGS 50.5K
- ANNX 1.7M
- Earning Date
- NGS 08-11-2025
- ANNX 08-11-2025
- Dividend Yield
- NGS N/A
- ANNX N/A
- EPS Growth
- NGS 76.16
- ANNX N/A
- EPS
- NGS 1.34
- ANNX N/A
- Revenue
- NGS $161,218,000.00
- ANNX N/A
- Revenue This Year
- NGS $13.56
- ANNX N/A
- Revenue Next Year
- NGS $15.42
- ANNX N/A
- P/E Ratio
- NGS $18.12
- ANNX N/A
- Revenue Growth
- NGS 22.64
- ANNX N/A
- 52 Week Low
- NGS $16.70
- ANNX $1.29
- 52 Week High
- NGS $29.74
- ANNX $7.85
- Technical
- Relative Strength Index (RSI)
- NGS 48.57
- ANNX 50.10
- Support Level
- NGS $22.72
- ANNX $2.29
- Resistance Level
- NGS $24.84
- ANNX $2.62
- Average True Range (ATR)
- NGS 0.77
- ANNX 0.18
- MACD
- NGS -0.02
- ANNX -0.01
- Stochastic Oscillator
- NGS 66.39
- ANNX 50.94
About NGS Natural Gas Services Group Inc.
Natural Gas Services Group Inc provides natural gas compression equipment and services to the energy industry. The company manufactures, fabricates, rents, sells, and maintains natural gas compressors and flare systems for oil and natural gas production and plant facilities. Its operating units include Rental, Sales, and Aftermarket services. The company generates the majority of its revenue by renting out low- to medium-horsepower compression equipment to natural gas production companies in unconventional oil and gas regions of the United States.
About ANNX Annexon Inc.
Annexon Inc is a clinical-stage biopharmaceutical company developing a pipeline of novel therapies for patients with classical complement-mediated disorders of the body, brain, and eye. Its pipeline is based on its platform technology addressing well-researched classical complement-mediated autoimmune and neurodegenerative disease processes, both of which are triggered by aberrant activation of C1q. Its pipeline of product candidates is designed to block the activity of C1q and the entire classical complement pathway in a broad set of complement-mediated diseases. Its product candidates are ANX005, for autoimmune & neurodegenerative disorders; ANX007, for neurodegenerative ophthalmic disorders; ANX1502 for Oral small molecule; and ANX009, for systemic autoimmune diseases.